Scilex Holding (SCLX) Total Current Liabilities (2020 - 2026)
Scilex Holding (SCLX) posted quarterly Total Current Liabilities of $501.8 million for Q1 2026, up 81.96% year-over-year from $275.7 million in Q1 2025, and up 3.74% on a QoQ basis from $483.7 million in Q4 2025.
Scilex Holding (SCLX) Total Current Liabilities (2020 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Total Current Liabilities for 7 consecutive years, with $501.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 81.96% year-over-year to $501.8 million; the TTM figure through Mar 2026 stood at $501.8 million (up 81.96% YoY), while the FY2025 annual figure was $483.7 million, up 86.28% from the prior year.
- Total Current Liabilities came in at $501.8 million for Q1 2026 at Scilex Holding, up from $483.7 million in the prior quarter.
- The five-year high for Total Current Liabilities was $501.8 million in Q1 2026, with the low at $41003.0 in Q1 2022.
- Average Total Current Liabilities over 5 years is $215.8 million, with a median of $252.7 million recorded in 2024.
- Across the five-year window, Total Current Liabilities tumbled 73.53% in 2022 and surged 157454.33% in 2023, its largest moves.
- Year by year, Total Current Liabilities stood at $44.8 million in 2022, then jumped by 458.36% to $250.4 million in 2023, then rose by 3.7% to $259.6 million in 2024, then soared by 86.28% to $483.7 million in 2025, then climbed by 3.74% to $501.8 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $501.8 million, $483.7 million, and $358.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 36.63 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 57.72 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 42.10 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -32.57 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 26.95 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 24.96 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 9.48 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 34.35 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | 501.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 501.75 Mn |
| Dec 31, 2025 | 483.65 Mn |
| Sep 30, 2025 | 358.95 Mn |
| Jun 30, 2025 | 305.93 Mn |
| Mar 31, 2025 | 275.74 Mn |
| Dec 31, 2024 | 259.64 Mn |
| Sep 30, 2024 | 281.54 Mn |
| Jun 30, 2024 | 255.45 Mn |
| Mar 31, 2024 | 252.73 Mn |
| Dec 31, 2023 | 250.38 Mn |
| Sep 30, 2023 | 228.58 Mn |
| Jun 30, 2023 | 103.58 Mn |
| Mar 31, 2023 | 64.60 Mn |
| Dec 31, 2022 | 44.84 Mn |
| Sep 30, 2022 | 809,292.00 |
| Jun 30, 2022 | 598,646.00 |
| Mar 31, 2022 | 41,003.00 |
| Dec 31, 2021 | 169.42 Mn |
| Sep 30, 2021 | 43,569.00 |
| Jun 30, 2021 | 20,025.00 |